Protocol Ledger

NCT04920617 · Phase II · RECRUITING

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventional Phase II clinical trial protocol NCT04920617 sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-18 Enrollment: 102 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04920617
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)102 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04920617
Protocol FieldVerified Registry Value
NCT IdentifierNCT04920617
Consolidated Lead SponsorImmunoVaccine Technologies, Inc. (IMV Inc.)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment102 participants (ESTIMATED)
Registered Start Date2021-06-18
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI